Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
NCT06594939Phase 2Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab and polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Medical College of Wisconsin. Primary endpoint: Complete Response up to 6 months. Started Jun 2026; status: recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06594939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594939.